Skip to main content
. Author manuscript; available in PMC: 2013 Jul 15.
Published in final edited form as: Lab Invest. 2011 Feb 14;91(4):598–608. doi: 10.1038/labinvest.2010.205

Figure 5. Sorafenib treatment maintained the CD4 and CD8 cells in spleen and lymph nodes.

Figure 5

A representative flow cytometric data showing the CD4+and CD8+ T cells frequency of gated lymphocytes in spleen and lymph nodes from normal and HCC tumor-bearing mice treated with solvent or soarfenib. Numbers in the figures represent the percentage of fluorescence-positive cells in corresponding areas, representative data of three independent experiments.